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Abstract 
Binding of ~rokinase-TV piasmin~ge~ activator (u-PA) to u-PA receptor (u-PAR) induces the rapid and transient expression of c-fir in GC-7 
ovarian carcinoma cells. The pretreatment of the cells with protein tyrosine kinase (PTK) inhibitors, but not the inactivation of the u-PA active site 
by DFP (diisopropyl fluorophosphate), abrogates this effect. A soluble u-PAR fragment, expressed in baculovirus-infected Sfp cells and purified by 
aRlnity chromato~aphy, competes for binding of u-PA to u-PAR and inhibits c-&r induction. We conclude that activation of u-PAR after interaction 
with u-PA at the cell surface initiates a transmembrane signal, most likely in conjunction with other still unknot protein(s), This signal generates 
PTK activity feeding into a signal transduction pathway which activates nuclear transcription factors. 
Key wolrds: I~edi~te early gene expression; Plasminogen activator; Urokina~-ty~ plasminogen activator receptor; Human 
ovarian Cancer cell; Signal ~ansduction 
Invasion and metastasis of solid tumors require the 
action of tumor-associated proteases which promote the 
dissolution of the surrounding cellular matrix and base- 
ment membranes [ 1 J. u-PA appears to play an important 
role in these events [ZJ. In addition to its proteolytic 
activity, u-PA interacts as a ligand with its specific recep- 
tor. Whereas it is generally held that the receptor focuses 
u-PA activity in space and time 133, recent data indicate 
that u-PAR, after the binding of u-PA, might interact 
with other transmembrane proteins in order to transduce 
a signal [4]. We have shown recently that in histiocytic 
lymphoma cells (U937) u-PA acts as an effector by acti- 
vating a protein tyrosine kinase [5]. The distal compo- 
nents of this signalling pathway, which might regulate 
cell proliferation, are u~nown, Likely candidates for 
such a role could be products of i~ediate early genes, 
which are essential for the stimulation of cell prolifera- 
tion by growth factors [6]. Therefore we investigated the 
effects of u-PA on c-j&r gene expression in E-7 human 
ovarian cancer cells, and report here that activation of 
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abbreviation: u-PA, urokinase-type plasminogen activator; u-PAR, u- 
PA receptor; PTK, protein tyrosine kinase; PMA, phorbol1Zmyristate 
acetate; DFP, diisopropyl fluorophosphate~ PBS, phospha~-buffers 
saline; SDS, sodium dodecylsulphate; PAGE, ~lyac~l~ide gel elec- 
trophoresis; DTT, dithiothreitol; BSA, bovine serum albumin; FSC, 
fetal calf serum; SSC, 0.15 M NaClZO.015 M Na,-citrate, pH 7.0. 
u-PAR by u-PA induces a rapid and transient expression 
of c-&s which is mediated via a tyrosine kinase. 
2. Materials and methods 
2.1. Materials 
Chemicals were of the best commerci~ grade available and pur- 
chased from Sigma (St. Louis, MO), Pharmacia LICB Biotechnology 
(Uppsala, Sweden), Merck (Darmstadt, Germany) or Serva (Hei- 
delberg, Germany). Radiochemicals were obtained from Amersham 
International (Little Chalfont, GB), PI-specific PLC was from Sigma, 
the protein tyrosine kinase inhibitors Herbimycin A (streptomyces 
spp.) and erbstatin analogue (methyl-2,5dihydroxy~nnamate) were 
from Calbiochem Biochemicals (San Diego, USA), u-PA was from 
Serono (Freiburg, Germany), anti-u-PAR monoclonal antibody (prod- 
uct #3936) was purchased from American Diagnostic Inc. 
(Greenwich, USA), purified rabbit anti-phosphot~osine polyclonal an- 
tibody from Dianova (Hamburg, Germany). The mRNA purification 
kit was obtained from Pharmacia LKB Biotechnology (Uppsala, Swe- 
den) and the multiple DNA labelling system was from DuPont NEN 
(Boston, USA). All cell culture media and the FCS were provided by 
Gibeo (Karlstein, Germany). 
2.2. Cell culture 
OC-7 cells, a cell line isolated from a human cystaden~a~inoma, 
were provided by Prof. M. Schmitt (Technical University Munich, 
Ge~any) and grown in DMEM/Ham’s Ft2 nutrient mix containing 
5% FSC _,_ _ --.
Sl9 insect cells were received from the European Collection of Ani- 
mal Cell Cultures (ECACC, Porton Down, Wilts, UK) and either 
propagated in supplemented Grace Insect (TNMFH) medium contain- 
ing 10% FCS and 0.1% pluronic (Serva, Heidelberg, Germany) or 
adapted to growth in serum-free medium (Sf 900 II medium) in this 
laboratory. 
2.3. ~~ectro~~ores~, Western blotting md outorud~ograF~y 
SDS-PAGE was carried out in slab gels (7.5, IO or 12.5%) as de- 
scribed 171. Samples were reduced immediately before eiectrophoresis 
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in the presence of 20 mM DTT for 5 min at 95’C or analysed under 
non-reducing conditions. Gels were electroblotted onto nitrocellulose 
sheets which were subsequently blocked with 1% BSA or 30% FCS [5]. 
Autoradiography of radiolabelled proteins was performed at -70°C 
with dried polyacrylamide gels using Konica X-ray film. 
2.4. Protein determ~at~~n 
Protein was quantified using a bicinchoninic acid (BCA) reagent 
from Pierce, using BSA as a standard. 
2.5. Northern blot unafysis 
Total RNA was isolated from 5 x IO7 cells by the guan~dinium iso- 
thiocyanate method as described in [8]. In some experiments polyad- 
enylated RNA was purified from total RNA on oligo(dT)~ellulose 
columns using a mRNA purification kit. 20 @g of total RNA or 5 pg 
of polyadenylated RNA were separated on 1% agarose-18% formalde- 
hyde gels and transferred onto GeneScreen Plus sheets by capillary 
force. A fragment of the C-&OS gene (1 kb) was labelied with r2P]dCTP 
by random priming [9]. The membranes were prehybridised in a solu- 
tion containing 50% formamide, 1% SDS, 10% d~xtranes~fate, 1 M 
NaCl at 42°C for 6 h and then hvbridised with a labelled nrobe (1 x lo6 
cp~ml) in the presence of denature salmon sperm DNA (lO~~~m1) 
at 42°C overnight. The filters were washed twice with 2 x SSC (each 
time for 5 mm at room temperature), followed by another two washes 
with 2 x SSCll % SDS (each time for 30 min at 60°C). Finally the filters 
U-PA - + + c 
DFP - - + 
c-fos 
were dried at room temperature and exposed to Konica X-ray film at 
-70°C. 
2.6. Construction of a recombinarnt bacufovirus, express&g s&bubte 
u-PAR 
The complete cDNA of the human u-PAR was obtained from Dr. 
E.K.O. Kruithof (Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland). Using synthetic primers corresponding to the published 
u-PAR cDNA sequence {IO], a 922 bp PCR fragment was amplified 
corresponding to the amino terminal 285 amino acids of the receptor, 
lacking the site for attachment of the GPI anchor. The primers were 
designed so that a S-end EcoRI site and a 3’-end BgfiI site were 
generated at each end of the fragment. Via these two restriction sites, 
the truncated u-PAR cDNA was inserted into the polylinker site of the 
baculovirus transfer vector, pVL1393 (InVitrogen, San Diego, CA, 
USA) downstream of the polyhedrin promoter. 
A recombinant baculovirus was then constructed by co-transfection 
of St9 insect cells with the transfer vector DNA together with linearized 
viral DNA (Baculogold virus DNA from Pharmingen, Palo Alto, CA, 
USA). Transfection and isolation of the recombinant virus was per- 
formed as described [l 11. Soluble U-PAR was produced by infection of 
St9 cells adapted to growth in serum-free medium (Sf 900 II medium; 
G&o) with the recombinant virus at a multiplicity of infection of 5. 
The culture su~rnat~t from infected cells containing the secreted 






Fig. 1. u-PA-induced c-fos gene expression in OC-7 cells. (a) The cells were stimulated with different concentrations of u-PA for 30 min. Total RNA 
(20 pg} was analysed by Northern blot hyb~disation as described in section 2. Human ~~lophilin (cph) mRNA levels were assessed as a control. 
(b) The cells were incubated with 100 nM u-PA for O-160 min. (c) u-PA was inactivated by the treatment with 20 mM DFP for 2 h at room temperature 
(right lane). (d) GC-7 cells were pretreated with Herbimycin A (1 PM/~ x 10’ cells) for 1 b at 37°C before u-PA stim~ation (lane 2); lane 1, control; 
lane 3, stimulation with u-PA (100 nM, 30 min); lane 4, stimulation with PMA (150 nM) for 2 h. 
u-PAR was purified from culture supernatants by &nity chronta- 
tography on u-PA-Sepharose which was prepared as previously de- 
scribed [5]. The supernatant containing the expressed u-PAR was 
passed over u-PA-Sepharose in the presence of 1 M NaCl. Bound 
u-PAR was eluted from the column with 0.2 M acetic acid adjusted to 
pN 1.8 by the addition of HCI and immediately neutral&d with Tris 
to pN 8.0. Before the assay, u-PAR was dialysed against PBS and 
concentrated using polyethylene glycol (M, = 20,000). Amino-terminal 
amino acid sequence analysis of u-PAR was performed after electro- 
phoretic transfer of the protein from po~yac~~~~de to Imrnobifon 
membranes. 
3. Ret&s and discussion 
3.1. u-PA-irzduced c-fos gene expremion 
Northern blot analysis demonstrated that u-PA-in- 
duced c-fos expression was dose-dependent (Fig. la) and 
that the increase in mRNA started at physiological con- 
centrations of the ligand. 
Of additional interest was the time-cams@ of the induc- 
tion, in compa~son to other effecters [12]. As shown in 
Fig. lb, the mRNA level reached a rn~irn~ after 30 
min treatment and declined to undetectable levels after 
120 min. This type of kinetics resembles the one previ- 
ously described in the context of mitogen-induced c-fos 
expression 1131, but not the type observed after induction 
with muscarinic receptor agonists and platelet-activating 
factor where ~ansc~ption stated within 1 min and de- 
tectable signals were observed as early as 5 min after 
ligand addition 1141, 
In order to exclude a p~t~n~al ~~~t~bution of prote- 
o&tic activity to the m~hanism of induction, u-PA was 
inactivated with DFP (Fig. 1~). This material induced the 
same level of expression, corroborating previous findings 
that demonstrated the involvement of proteolytically in- 
active u-PA in signalling events [4,5], Stimulation of ty- 
rosine kinases is a common denominator of various sig- 
nalliag pathways (including signalling via GPI-anchored 
proteins, [ 151) ultimately leading to the activation of nu- 
clear transcription factors [16]. Pretreatment of cells for 
20 min with Herbimycin A, an inhibitor of protein tyro- 
sine kinase activity, completely inhibited u-PA-induced 
signal transduction (Fig. Id). The same results were ob- 
tained with the erbstatin ~alogue (data not shown). 
PEA-treated cells served as a positive control. 
chromatography on u-PA-Sepharose, was subjected to 
SDS-PAGE and Western blot analysis. Under non-re- 
ducing conditions one prominent band (M, u 35 kDa) was 
stained by Coomassie blue R-250 (Fig. 2a) and revealed 
by Western blot analysis using pol~~lo~al nd mono&- 
nal anti-u-PAR antibody (data not shows). The amino 
acid sequence of purified S&u-PAR was dete~ned by 
Wh 
Fig. 2, (a) Purification of recombinant %9-u-PAR by affinity chroma- 
tography. Details of the purification are des&?ed in the text. The 
samples were stained by Coomassie blue R-250. Lane 1, fraction after 
a&&y chro~ato~aphy; lane 2, ~o~e~~sr weight markers {20,30,43, 
57 and 97 kDa). fb) u-PA (20 nM) was preincubated with increasing 
con~~tra~o~s of r~o~bina~~t u-PAR and then incubated with the cells 
as described in the text. RNA extraction and Northern blot analysis 
were carried out as described in section 2. 
automated Edmann degradation and shown to corre- 
spond to a real one. The reduced M, of the fragment 
indicted incomplete gly~osylation during heterologous 
expression. These data established uniquivocally that the 
purified material consisted of authentic, truncated u- 
PAR. 
3.3. ~~~pe~~t~~n for ~~nd~~g by ~~~~~@ u-PAR 
Recombinant u-PAR was used in order to obtain some 
further evidence for c-fos expression by u-PA induction. 
For this purpose a competition assay was performed. 
u-PA was preincubated with increasing concentrations 
of recombinant S&u-PAR and then incubated with OC- 
7 cells for 30 min. The induction of c-$&s expression in 
all probes was evaluated by Northern blot analysis. The 
data presented in Fig. Zb, clearly show that recombinant 
u-PAR competed with binding of u-PA to u-PAR and 
interfered with u-PA-induce c--~ expression in a dose- 
dependent fashion. A 30-fold molar excess af recombi- 
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nant Sf%t-PAR almost completely prevented the induc- 
tion. Our results allow the following conclusions. (i) u- 
PA transduces ignals to the nuclear transcriptional ap- 
paratus via u-PAR. This effect most likely requires the 
interaction of u-PAR with still undefined additional pro- 
tein(s). (ii) The signal is generated inde~ndently of u-PA 
proteolytic activity, and (iii) involves the activation of a 
tyrosine kinase. What we described represents probably 
a novel pathway of growth control that might be accessi- 
ble to therapeutic intervention. 
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